Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 463 results

Media Release / Mar 06, 2017

Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
Media Release / Sep 16, 2016

Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs
Media Release / May 20, 2016

Media Statement: Leading US cardiology societies strongly recommend Entresto® as a new standard of care treatment in an earlier-than-expected joint update of clinical practice guidelines for heart failure
Media Release / May 26, 2021

Novartis commits to addressing racial disparities in breast cancer screening, treatment and care
Media Release / May 27, 2020

Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)
Media Release / Mar 28, 2020

Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Media Release / Feb 11, 2020

Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Media Release / Dec 11, 2019

Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps
Media Release / Jul 11, 2019

Novartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions
Media Release / Mar 28, 2023

Novartis ribociclib (Kisqali®) only Category 1 preferred first-line treatment option for HR+/HER2- mBC in combination with an AI in updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

East Hanover, March 28, 2023 — Updates to the NCCN Guidelines® for breast cancer, released in January 2023, recommend ribociclib (Kisqali®) as the only Category 1 preferred CDK4/6 inhibitor (…